Literature DB >> 6582301

A rapid assay for cytotoxicity of unstimulated human monocytes.

H W Ziegler-Heitbrock, G Riethmüller.   

Abstract

Human peripheral blood mononuclear cells were used as effectors against the Wehi 164 mouse fibrosarcoma cell line grown in suspension culture. In a standard 7-hour 51Cr release assay, specific release usually was below 10%. In contrast, pretreatment of Wehi 164 for 3 hours with dactinomycin (Act D), while leaving the tumor cells intact and viable, resulted in a drastic increase in its susceptibility to lysis, which reached 60% specific release. In terms of lytic units, this reflects up to a fiftyfold enhancement. Cell-separation experiments revealed that the effector cells were plastic-adherent and iron-phagocytic. Adherent cell fractions with 85-98% naphthol AS acetate-esterase (NAS)-positive cells were enriched in cytotoxicity, while nonadherent cells with less than 4% NAS-positive cells were almost devoid of activity. Depletion of phagocytic cells with iron and magnet resulted in a strong reduction of cytotoxicity by 82-95% compared to the cytotoxicity seen in control treated effector cells. In both kinds of analyses, natural killer cell activity showed a reciprocal behavior. The evidence indicates that the cytotoxic effector cells directed against Act D-treated Wehi 164 cells belong to the monocyte lineage. The system described should be useful in analyzing the cytotoxic function of unstimulated monocytes in a short-term assay without prior purification of the effector cells.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6582301     DOI: 10.1093/jnci/72.1.23

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  16 in total

1.  Increased tumor necrosis factor-alpha (TNF-alpha) gene expression in parainfluenza type 1 (Sendai) virus-induced bronchiolar fibrosis.

Authors:  E W Uhl; L L Moldawer; W W Busse; T J Jack; W L Castleman
Journal:  Am J Pathol       Date:  1998-02       Impact factor: 4.307

2.  Enhanced susceptibility of target KMT-17 cells to activated macrophages by treatment with the antitumor agent bleomycin.

Authors:  Z Y Xu; M Hosokawa; K Morikawa; H Kobayashi
Journal:  Cancer Immunol Immunother       Date:  1986       Impact factor: 6.968

3.  Interferon gamma encapsulated into liposomes enhances the activity of monocytes and natural killer cells and has antiproliferative effects on tumor cells in vitro.

Authors:  I Rutenfranz; A Bauer; H Kirchner
Journal:  Blut       Date:  1990-07

4.  Granulocyte-macrophage colony-stimulating factor induces cytokine secretion by human polymorphonuclear leukocytes.

Authors:  A Lindemann; D Riedel; W Oster; H W Ziegler-Heitbrock; R Mertelsmann; F Herrmann
Journal:  J Clin Invest       Date:  1989-04       Impact factor: 14.808

5.  Monocyte-mediated drug-dependent cellular cytotoxicity: effects on different WEHI 164 target cell lines.

Authors:  R Austgulen; O Kildahl-Andersen; T Espevik
Journal:  Cancer Immunol Immunother       Date:  1986       Impact factor: 6.968

6.  Transforming growth factor-beta 1 inhibits activation of macrophage cell line RAW 264.7 for cell killing.

Authors:  M Haak-Frendscho; T A Wynn; C J Czuprynski; D Paulnock
Journal:  Clin Exp Immunol       Date:  1990-11       Impact factor: 4.330

Review 7.  Tumor necrosis factor (TNF) alpha: control of TNF-sensitivity and molecular mechanisms of TNF-mediated growth inhibition.

Authors:  K Pfizenmaier; M Krönke; P Scheurich; G A Nagel
Journal:  Blut       Date:  1987-07

8.  Rapid killing of actinomycin D-treated tumour cells by mononuclear phagocytes: reactivity in mouse strains with defective classical tumour cytotoxicity.

Authors:  F Collota; L Bersani; N Polentarutti; A Mantovani
Journal:  Immunology       Date:  1986-02       Impact factor: 7.397

9.  The synergistic tumoricidal activity of anticancer drugs and oxidative burst-triggered macrophages.

Authors:  S Marcovitch; Y Keisari
Journal:  Cancer Immunol Immunother       Date:  1985       Impact factor: 6.968

10.  Tumor necrosis factor: recent advances.

Authors:  R Munker; H P Koeffler
Journal:  Klin Wochenschr       Date:  1987-04-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.